Yayasan KNCV Indonesia

What Yayasan KNCV Indonesia does

Yasa Karsa Insani (YKI), formerly known as Yayasan KNCV Indonesia, is an Indonesian nonprofit foundation headquartered in North Jakarta that delivers technical assistance, operational research, and capacity-building programs focused on tuberculosis (TB), HIV, and broader public health system strengthening. Founded in 2016 and operating for nearly a decade, YKI implements donor-funded public health programs in partnership with Indonesia's Ministry of Health, district/city health offices, hospitals, primary healthcare centers (Puskesmas), civil society organizations, and community cadres across dozens of provinces and districts.

The organization's core service portfolio comprises multiple concurrent grant-funded projects: LIFT-TB (BPaL regimen scale-up), ASCENT DR-TB (MESO Active drug safety monitoring), Mandiri-TB (community mobilization for DR-TB), HARAPAN (private-sector TB financing), ENTAS TB (district-level elimination), AMPUH and AKSES VL (HIV viral load testing expansion), and the One To Three Study (Phase IV clinical trial of TPT regimens). YKI has developed and deployed an integrated suite of digital tools—SITRUST HIV for specimen tracking, EMPATI for DR-TB patient monitoring, SiMESO for adverse event reporting, SOBAT TB for community screening, and REDCap-based pharmacovigilance systems—interoperable with national TB (SITB) and HIV (SIHA) information systems.

YKI operates a non-commercial revenue model funded entirely through grants from international development organizations and bilateral donors (USAID, The Global Fund, KOICA, Unitaid, World Bank, Bill & Melinda Gates Foundation, TB Alliance) and corporate CSR (PT Agincourt Resources). In 2025, YKI rebranded from Yayasan KNCV Indonesia to Yasa Karsa Insani, signaling a deliberate strategic expansion beyond its TB origins into non-communicable diseases and broader health systems strengthening, while maintaining its core TB and HIV mandate.

Name

Yayasan KNCV Indonesia

Legal name

Yasa Karsa Insani

Website

https://yki4tbc.org

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Yasa Karsa Insani (YKI) is an Indonesian nonprofit foundation that delivers donor-funded technical assistance, digital health tools, and operational research for tuberculosis, HIV, and broader public health systems across dozens of Indonesian provinces, in partnership with the Ministry of Health and community organizations.

Ownership category

akta.pro rank

Product category

Public Health Program Implementation and Technical Assistance

NAICS

Voluntary Health Organizations (813212), Religious, Grantmaking, Civic, Professional, and Similar Organizations (813), Other Computer Related Services (541519)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731), Services-Computer Programming Services (7371)

akta.pro primary industry

Health Systems Strengthening & Global Health Technical Assistance (BPADAEAH)

akta.pro secondary industries

Communicable Disease Prevention & Control (HIV/AIDS, TB, Malaria, NTDs) (BPADAIAA), Digital Health, Health Information Systems & Data Programs (BPADAIAJ), Disease-Specific Global Programs (HIV/TB/Malaria/NTDs) (HLAJAKAF)

Keywords

• Tuberculosis program implementation
• HIV viral load testing
• Public health technical assistance
• Health system strengthening
• Community health mobilization

Headquarters

HQ city

Jakarta

HQ country

Indonesia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. International Development Grants: YKI operates as a non-profit foundation funded primarily through grants and technical assistance agreements from international development organizations and bilateral donors. These grants fund specific public health programs in TB, HIV, and health systems strengthening across Indonesia.
2. Corporate Social Responsibility (CSR) Funding: YKI mobilizes corporate social responsibility contributions from private companies (e.g., PT Agincourt Resources) to co-finance community-based TB initiatives, patient support activities, and local health programs. The Mandiri-TB project facilitated CSR proposal submissions securing funding for local initiatives.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Yasa Karsa Insani (YKI) is an Indonesian non-profit foundation that designs and implements donor-funded public health programs focused on tuberculosis (including drug-resistant TB), HIV, and health system strengthening. It delivers technical assistance, operational research, capacity building, and policy advocacy to the Ministry of Health and provincial/district health authorities, and it develops and deploys digital health tools (SITRUST HIV, EMPATI, SOBAT TB, SiMESO, REDCap-based systems) to support case detection, treatment adherence, pharmacovigilance, and laboratory specimen logistics.

Product overview

Yasa Karsa Insani (YKI), formerly known as Yayasan KNCV Indonesia, is a health-focused foundation that integrates science, innovation, and community needs to deliver data-driven solutions improving lives across Indonesia. The organization's offerings span a multi-program portfolio centered on TB and HIV prevention and care, a growing non-communicable disease (NCD) initiative, and health systems strengthening. In TB, key programs include LIFT-TB (BPaL regimen scale-up), ASCENT DR-TB (active drug safety monitoring), Mandiri-TB (community mobilization), ENTAS TB (local elimination), and HARAPAN (private sector TB financing). HIV programming includes AMPUH and AKSES VL (viral load testing expansion). YKI's digital product portfolio includes SITRUST HIV (specimen tracking), EMPATI (DR-TB patient monitoring mobile app), and SOBAT TB (community screening and contact investigation). The One To Three Study generates operational evidence for TB preventive therapy. YKI's service model combines technical assistance, operational research, capacity building, and digital transformation support—all guided by WHO frameworks and aligned with Indonesia's national health priorities.

Differentiator

Problem solved

Functional benefit

Products and services

• AMPUH (Accelerating Viral Load Testing Among PLHIV through SITRUST and High-Quality Laboratories) Global Fund-supported initiative accelerating HIV viral load testing among people living with HIV through SITRUST digital integration, laboratory quality improvement, and health worker training across 105 districts in 34 provinces.
• AKSES VL (Accelerating Demand-making and Supply-side Strengthening for Optimal Access to HIV Viral Load Testing) Global Fund-funded initiative expanding equitable access to HIV viral load testing nationwide across 38 provinces, 514 districts, 2,443 CST facilities, and 235 HIV VL laboratories, with community engagement, specimen tracking, and laboratory quality improvement components.
• Mandiri-TB (Mobilizing Network for Self-Reliance to Fight Tuberculosis) USAID-funded community mobilization program for drug-resistant TB that established multi-sectoral forums, trained community cadres, and facilitated CSR funding for patient support, enrolling 383 DR-TB patients and training 420 cadres across 4 high-burden cities (Medan, North Jakarta, Surabaya, Makassar).
• LIFT-TB (Leveraging Innovation for Faster Treatment of Tuberculosis) KOICA and TB Alliance-supported initiative to introduce and scale up WHO-recommended 6-9-month BPaL regimen (bedaquiline, pretomanid, linezolid) for drug-resistant TB across 15 hospitals in 4 provinces, achieving 97.6% treatment success rate and enabling Indonesia's first Asia-Pacific programmatic adoption of BPaL/M.
• HARAPAN (Human Resources for Advancing Private-sector Health Access and Patient Assistance Network) World Bank and Bill & Melinda Gates Foundation-funded project enhancing private primary care provider capacity for TB financing and service delivery, improving case detection, data accuracy, and BPJS-K incentive claim utilization across Bogor, Semarang, and Surabaya.
• ENTAS TB (Menuju Tapanuli Selatan Bebas TBC) PT Agincourt Resources-funded project accelerating TB elimination in South Tapanuli through multi-sectoral collaboration, digital tools (SOBAT TB application), and local regulatory frameworks, including a Multi-sectoral Forum and District TB Action Plan 2023-2027.
• ASCENT DR-TB Unitaid-funded project providing technical assistance for active drug side effect monitoring (MESO Aktif) for drug-resistant TB patients across 24 districts/cities in South Sulawesi, including digital monitoring tools, telemedicine consultation platforms, and healthcare worker capacity building.
• One To Three Study Phase IV randomized clinical trial comparing 1HP (1 month) vs 3HP (3 months) tuberculosis preventive therapy regimens, generating local evidence for national TPT policy with 92% and 98% completion rates respectively; YKI is local sponsor and The Aurum Institute is global sponsor.
• SITRUST HIV (Sistem Informasi Rujukan Specimen Terpadu) Digital specimen tracking application (Sistem Informasi Rujukan Specimen Terpadu) that enables real-time referral, tracking, and reporting of HIV viral load specimens across laboratory networks, supporting logistics integration with national HIV reporting systems.
• EMPATI Mobile Application Mobile application for digital case monitoring and support of drug-resistant TB patients, enabling treatment adherence tracking, counselling, and communication between patients and case managers under the Mandiri-TB program.
• SOBAT TB Application Digital application for community-based TB screening, contact investigation, and patient support, used by health workers and cadres under the ENTAS TB project in South Tapanuli for TB case finding and treatment adherence monitoring.
• Knowledge Hub (Research Evidence Platform) Online repository of YKI's practical tools, policy guidance, and research evidence including PDFs such as Ishihara test books, TB RO side effect monitoring guides, treatment guidelines, Indonesia TB regulations, and research studies on BPaL treatment outcomes.
• Peduli Ulkus Diabetikum (Diabetic Ulcer Community Outreach) Community outreach initiative providing free diabetes wound consultation and examination services, conducted in partnership with RS Siloam Agora and Klinik Utama Previ as part of World Diabetes Day 2025 commemoration, focused on early detection and patient education.

Quantifiable outcome

• Achieved 97.6% treatment success rate for DR-TB patients on BPaL regimen with culture conversion within 3 months and no relapse cases
• +8 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Ministry of Health of the Republic of Indonesia (Kementerian Kesehatan RI)coreStrategic or Co-development PartnerThe Ministry of Health is a key strategic partner across all YKI programs. YKI provides technical assistance to the Ministry for national TB and HIV policy development, guideline formulation, program design, and implementation support. Key collaboration areas include BPaL regimen adoption, TPT scale-up, MESO Active implementation, and viral load testing expansion.
• Persatuan Karya Dharma Indonesia (PERDHAKI)coreStrategic or Co-development PartnerPERDHAKI is a civil society organization partner in the Mandiri-TB project, collaborating with YKI and the Ministry of Health to empower civil society and patient organizations for DR-TB community engagement, resource mobilization, and patient support in four high-burden cities.
• KNCV TB FoundationcoreStrategic or Co-development PartnerKNCV TB Foundation is the global lead of the LIFT-TB consortium, providing technical oversight and partnership with YKI for the introduction of the BPaL regimen in Indonesia. YKI was formerly known as Yayasan KNCV Indonesia, reflecting its historical affiliation with KNCV TB Foundation.
• Aurum InstitutecoreStrategic or Co-development PartnerThe Aurum Institute serves as the global sponsor of the IMPAACT4TB consortium and the One To Three Study, with YKI acting as the local sponsor in Indonesia. The partnership enables operational implementation and clinical research for short-course TB preventive therapy regimens.
• TB Community Organizations (Yamali TB, Yayasan Kareba Baji, Yayasan Daeng TB, patient organizations)coreStrategic or Co-development PartnerYKI partners with TB community organizations and patient groups for DR-TB patient counseling, treatment adherence monitoring, and community-led advocacy. These organizations participated in the ASCENT DR-TB dissemination meeting and represent the community voice in program design and implementation.
• International Tuberculosis Research Centre (ITRC)minorStrategic or Co-development PartnerITRC collaborated with YKI, the Ministry of Health, and KNCV TB Foundation on the LIFT-TB project, contributing to operational research and capacity strengthening for BPaL regimen implementation across 15 hospitals.
• RS Siloam AgoraminorStrategic or Co-development PartnerRS Siloam Agora partnered with YKI and Klinik Utama Previ to provide free diabetic ulcer consultations and examinations as part of World Diabetes Day 2025 commemorative activities on December 13, 2025, contributing specialist medical expertise and facility access.
• Klinik Utama PreviminorStrategic or Co-development PartnerKlinik Utama Previ hosted the World Diabetes Day 2025 community health event organized by YKI in partnership with RS Siloam Agora, providing free diabetic wound consultations and examinations and serving as the venue for community health outreach activities.
• BPJS KesehatanminorStrategic or Co-development PartnerBPJS Kesehatan collaborates with YKI under the HARAPAN project to facilitate private primary care provider access to TB service incentive claims, integrating private providers into the national TB program financing mechanism.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• KNCV Tuberculosis Foundation: YKI's historical parent/affiliated organization and current consortium partner on LIFT-TB and IMPAACT4TB. Operates as a Netherlands-based TB-focused technical assistance NGO with similar donor-funded program model and global TB mandate.
• The Aurum Institute: Global lead of the IMPAACT4TB consortium and co-implementer of the One To Three Study with YKI. A South Africa-based TB and HIV research and implementation organization with comparable donor-funded program structure and clinical research capabilities.

Broad incumbents

• TB Alliance: Product development partnership that developed pretomanid for the BPaL regimen and partnered with YKI through KNCV on LIFT-TB. Operates globally as a TB drug developer rather than a country implementer, but shares deep TB technical focus.
• Stop TB Partnership: Global UN-hosted partnership coordinating TB elimination efforts. YKI participated in World TB Day commemorations aligned with Stop TB's mission and frameworks. Comparable in TB focus but at global coordination rather than country implementation level.
• FHI 360: Large US-based global health and development implementer running USAID- and donor-funded health programs across multiple countries. Comparable as a donor-funded technical assistance provider with similar infectious disease and health systems strengthening portfolio.
• PATH: Global health innovation NGO that designs and implements donor-funded health programs with a focus on digital health, vaccines, and infectious disease. Comparable as a donor-funded implementer with digital health tool development expertise.
• Clinton Health Access Initiative (CHAI): Global health organization working with governments and donors to strengthen health systems and expand access to treatment. Comparable technical assistance and health systems strengthening model operating across multiple low- and middle-income countries.
• Jhpiego: Affiliated with Johns Hopkins, Jhpiego implements donor-funded health programs globally with strong focus on infectious disease, health worker training, and health systems strengthening. Highly comparable as a technical assistance implementer.

Regional players

• Spiritia Foundation: Indonesian HIV-focused non-profit supporting PLHIV through peer support, treatment literacy, and community engagement. Directly comparable as a domestic Indonesian non-profit working on HIV/AIDS with community and government partnerships.
• Indonesia AIDS Coalition: Indonesian civil society coalition advocating for PLHIV rights and access to treatment. Comparable as a domestic non-profit operating in the same Indonesian HIV ecosystem with similar government and donor engagement models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/YKI4TBC
• LinkedInlinkedin.com/company/yasakarsainsani

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yayasan KNCV Indonesia